BritePear›Research›Cagrilintide
Research · GLP-1 Pipeline
Phase III · NDA Under FDA Review

Cagrilintide, The Amylin Angle

The long-acting amylin analog behind CagriSema, and why targeting a different satiety pathway changes what weight loss medicine can achieve.

🍐 Pear It Down ,

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone your pancreas releases alongside insulin after meals to signal fullness through pathways GLP-1 does not reach. Combined with semaglutide as CagriSema, it produced 22.7% average weight loss vs. 16.1% for semaglutide alone in the REDEFINE 1 Phase 3 trial. NDA filed December 2025. FDA decision expected approximately October 2026.

Not medical advice. Educational content reflecting research and personal transparency. CagriSema is not yet FDA-approved. Always consult a licensed healthcare provider before starting any medication.

Most of the GLP-1 conversation focuses on one hormone and one receptor. Cagrilintide is a reminder that satiety, the feeling of fullness, is more complicated than that, and that targeting multiple pathways simultaneously produces better results than going deeper on one.

What Amylin Is

A Different Satiety Signal

Amylin is a peptide hormone co-secreted by the pancreatic beta cells alongside insulin in response to meals. While GLP-1 acts primarily on the brain's appetite regulation centers and the gut (slowing gastric emptying), amylin acts through different receptors in the brain's area postrema and hypothalamus to produce complementary satiety signals.[1]

The practical result: amylin and GLP-1 pathways are additive. When you stimulate both simultaneously, the satiety effect is greater than either hormone alone. This is the core biological rationale for CagriSema.

The Compound

Cagrilintide, Designed for Duration

Cagrilintide is a long-acting amylin analog, meaning it's engineered to have a much longer half-life than native amylin, which breaks down quickly in the body. This allows once-weekly dosing, matching the injection schedule of semaglutide, which is why the combination is practical as a single weekly injection.[2]

The compound was specifically developed by Novo Nordisk to pair with semaglutide, making CagriSema a fixed-dose combination product rather than two separate injections.

The Evidence

REDEFINE 1, The Phase 3 Data

The REDEFINE 1 Phase 3 trial was the pivotal study. 3,417 adults with obesity (without type 2 diabetes) were randomized to CagriSema or semaglutide alone over 68 weeks.[3]

22.7%Avg. weight loss, CagriSemaREDEFINE 1
16.1%Avg. weight loss, Semaglutide aloneREDEFINE 1
88%Pre-diabetic participants returning to normal glucoseREDEFINE 1

More than half of CagriSema participants lost 20% or more of body weight. The absolute weight loss numbers are compelling, and represent a meaningful step forward over semaglutide alone for many patients.

The Head-to-Head Against Tirzepatide

The REDEFINE 4 trial ran CagriSema directly against tirzepatide 15mg over 84 weeks. CagriSema achieved 23% weight loss, strong numbers. But it did not meet the primary endpoint of non-inferiority against tirzepatide.[4]

This is a clinically honest result worth understanding clearly: CagriSema is meaningfully better than semaglutide alone, and the absolute numbers are impressive. It just did not beat Zepbound in a direct comparison at those doses. That context matters when evaluating where CagriSema fits in the treatment landscape.

"For people currently on semaglutide, CagriSema is the most directly relevant pipeline compound to understand. It's the same GLP-1 foundation plus a different satiety pathway layered on top. The data suggests a meaningful improvement over what you're already doing."

The Regulatory Path

Where It Stands Now

Novo Nordisk filed the NDA for CagriSema on December 18, 2025. Based on the standard 10-month FDA review timeline, a decision is expected approximately October 2026. If approved, it would likely be available in the US by late 2026 or early 2027.

This page will be updated as regulatory decisions are made. For the broader pipeline context including Pemvidutide, oral GLP-1s, and other compounds in development, see the Pipeline section.

See the Full Pipeline, The Orchard →
⚠ FDA / Regulatory StatusCagriSema (cagrilintide + semaglutide) is not yet FDA-approved. NDA filed December 18, 2025. FDA decision expected approximately October 2026. Do not pursue this compound outside of clinical trial enrollment, it is not currently available through any compounding or gray market pathway. Cagrilintide as a standalone compound is also not available outside of clinical trials.
Cliff's Note

The amylin story is one of those things that makes you appreciate how complex the biology of hunger actually is. For decades we thought of appetite regulation as mostly one system. The data on amylin combination therapy is a useful reminder that there are multiple pathways, and that pharmaceutical companies are just beginning to explore what happens when you target more than one at a time. The results from REDEFINE 1 are genuinely exciting, not because they beat everything else, but because they show that the ceiling on GLP-1 therapy is higher than a single receptor pathway suggests.

Sources & Citations

  1. Hay DL, et al. (2015). Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacological Reviews, 67(3), 564–600.
  2. Enebo LB, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of long-acting amylin analogue cagrilintide. The Lancet, 397(10284), 1541–1550.
  3. Christensen RM, et al. (2025). Cagrilintide 2.4 mg combined with semaglutide 2.4 mg (CagriSema) for obesity (REDEFINE 1). New England Journal of Medicine.
  4. Novo Nordisk press release. REDEFINE 4: CagriSema head-to-head versus tirzepatide. November 2025.